Association of arterial hypertension and periodontal disease: a review of new data

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Arterial hypertension (AH) and periodontitis are two widespread diseases worldwide that have a significant impact on the cardiovascular complications of diseases. Epidemiological data indicate a potential link between periodontitis and elevated blood pressure and the prevalence of AH. Over the past few years, the results of large-scale studies on the relationship between AH and periodontal pathology have been published, and possible mechanisms for this relationship are being actively discussed. The first part of the review is devoted to the analysis of new data on the relationship between AH and periodontitis using the PubMed and Scopus electronic databases. Recent studies, systematic reviews and meta-analyses support the relationship between periodontitis and AH. A joint report of the Italian Society of Hypertension (SIIA) and the Italian Society of Periodontology and Implantology (SIdP) has been published to raise the awareness of the medical community about the close relationship between these two conditions. Greek cardiologists coined the term stomatological hypertension. However, recommendations for the treatment of AH in patients with concomitant periodontitis are lacking. Calcium channel blockers are known to be the most common cause of drug-induced gingival hyperplasia. In this regard, in the second part of the review, the possibility of using the thiazide-like diuretic indapamide in patients of this category, taking into account its effectiveness, metabolic neutrality and safety, was considered.

Full Text

Restricted Access

About the authors

D. I. Trukhan

Omsk State Medical University

Author for correspondence.
Email: dmitry_trukhan@mail.ru
ORCID iD: 0000-0002-1597-1876

Dr. Sci. (Med.), Associate Professor, Professor of the Department of Polyclinic Therapy and Internal Diseases

Russian Federation, Omsk

A. F. Sulimov

Omsk State Medical University

Email: dmitry_trukhan@mail.ru
Russian Federation, Omsk

L. Yu. Trukhan

Omsk State Medical University

Email: dmitry_trukhan@mail.ru
ORCID iD: 0000-0002-4721-6605
Russian Federation, Omsk

References

  1. Клинические рекомендации (протоколы лечения) при диагнозе пародонтит. [Clinical guidelines (treatment protocols) in the diagnosis of periodontitis. (In Russ.)]. URL: http://www.e-stomatology.ru/director/protokols_30-09-2014
  2. Всемирная организация здравоохранения. Информационные бюллетени. Охрана здоровья полости рта. [World Health Organization. Newsletters. Oral health care. (In Russ.)].URL: https://www.who.int/ru/news-room/fact-sheets/detail/oral-health
  3. Трухан Д.И., Трухан Л.Ю. Взаимоотношения болезней пародонта и сердечно-сосудистых заболеваний. Международный журнал сердца и сосудистых заболеваний. 2016;4(11):15–24. [Trukhan D.I., Trukhan L.Yu. The relationship between periodontal disease and cardiovascular disease. Mezhdunarodnyi zhurnal serdtsa i sosudistykh zabolevanii. 2016;4(11):15–24. . (In Russ.)].
  4. Van Dyke T.E., Starr J.R. Unraveling the link between periodontitis and cardiovascular disease. J Am Heart Assoc. 2013;2(6):e000657. doi: 10.1161/JAHA.113.000657.
  5. Mancia Chairperson G., Kreutz Co-Chair R., Brunstrom M., et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023 Jun 21. doi: 10.1097/HJH.0000000000003480.
  6. Del Pinto R., Pietropaoli D., Munoz-Aguilera E., et al. Periodontitis and Hypertension: Is the Association Causal? High Blood Press. Cardiovasc Prev. 2020;27(4):281–89. doi: 10.1007/s40292-020-00392-z.
  7. Трухан Д.И., Трухан Л.Ю. Пародонтит и сердечно-сосудистые заболевания: параллельно или в одной связке? Consilium Medicum. 2015;5:73–9. [Trukhan D.I., Trukhan L.Yu. Periodontitis and cardiovascular diseases: in parallel or in one bundle? Consilium Medicum. 2015;5:73–9. (In Russ.)].
  8. Трухан Д.И., Трухан Л.Ю. Некоторые аспекты коморбидности пародонтита и сердечно-сосудистых заболеваний. Медицинский совет. 2015;17:12–6. [Trukhan D.I., Trukhan L.Yu. Some aspects of comorbidity of periodontitis and cardiovascular diseases. Meditsinskiy sovet. 2015;17:12–6. (In Russ.)].
  9. Сулимов А.Ф., Трухан Л.Ю., Тимашов В.Н. Изменения органов и тканей полости рта при артериальной гипертензии и других заболеваниях сердечно-сосудистой системы. Справочник поликлинического врача. 2020;1:39–42. [Sulimov A.F., Trukhan L.Yu., Timashov V.N. Changes in the organs and tissues of the oral cavity in arterial hypertension and other diseases of the cardiovascular system. Spravochnik poliklinicheskogo vracha. 2020;1:39–42. (In Russ.)].
  10. Трухан Д.И., Трухан Л.Ю., Иванова Д.С. Коморбидность заболеваний сердечно-сосудистой системы и болезней органов пищеварения с изменениями органов и тканей полости рта. Клинический разбор в общей медицине. 2021;3:6–17. [Trukhan D.I., Trukhan L.Yu., Ivanova D.S. Comorbidity of diseases of the cardiovascular system and diseases of the digestive system with changes in the organs and tissues of the oral cavity. Klinicheskii razbor v obshchei meditsine.2021;3:6–17. (In Russ.)]. doi: 10.47407/kr2021.2.3.00044.
  11. Трухан Д.И., Сулимов А.Ф., Трухан Л.Ю. Возможные ассоциации патологии пародонта и новой коронавирусной инфекции (COVID-19). Клинический разбор в общей медицине. 2022;2:6–12. [Trukhan D.I., Sulimov A.F., Trukhan L.Yu. Possible associations of periodontal pathology and novel coronavirus infection (COVID-19). Klinicheskii razbor v obshchei meditsine. 2022;2:6–12. (In Russ.)]. doi: 10.47407/kr2022.3.2.00120.
  12. Tsioufis C., Kasiakogias A., Thomopoulos C., Stefanadis C. Periodontitis and blood pressure: the concept of dental hypertension. Atherosclerosis. 2011;219(1):1–9. doi: 10.1016/j.atherosclerosis.2011.04.030.
  13. Leong X.F., Ng C.Y., Badiah B., Das S. Association between hypertension and periodontitis: possible mechanisms. Sci W J. 2014;2014:768237. doi: 10.1155/2014/768237.
  14. Franek E., Napora M., Blach A., et al. Blood pressure and left ventricular mass in subjects with type 2 diabetes and gingivitis or chronic periodontitis. J Clin Periodontol. 2010;37(10):875–80. doi: 10.1111/j.1600-051X.2010.01613.x.
  15. Vieira C.L., Cury P.R., Miname M.H., et al. Severe periodontitis is associated with diastolic blood pressure elevation in individuals with heterozygous familial hypercholesterolemia: a pilot study. J. Periodontol. 2011;82(5):683–88. doi: 10.1902/jop.2010.100496.
  16. Vidal F., Figueredo C.M., Cordovil I., Fischer R.G. Higher prevalence of periodontitis in patients with refractory arterial hypertension: a case-control study. Oral Dis. 2011;17(6):560–63. doi: 10.1111/j.1601-0825.2011.01800.x.
  17. Zhang L., Li Y.F., Liang Z.Z., et al. The association between chronic periodontitis and hypertension in rural adult Uygur residents. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39(12):1140–44. https://pubmed.ncbi.nlm.nih.gov/22336509
  18. Iwashima Y., Kokubo Y., Ono T., et al. Additive interaction of oral health disorders on risk of hypertension in a Japanese urban population: the Suita Study. Am J Hypertens. 2014;27(5):710–19. doi: 10.1093/ajh/hpt227.
  19. Jockel-Schneider Y., Harks I., Haubitz I., et al. Arterial stiffness and pulse wave reflection are increased in patients suffering from severe periodontitis. PLoS One. 2014;9(8):e103449. doi: 10.1371/journal.pone.0103449.
  20. Zeigler C.C., Wondimu B., Marcus C., Modeer T. Pathological periodontal pockets are associated with raised diastolic blood pressure in obese adolescents. BMC. Oral Health. 2015;15(1):41. doi: 10.1186/s12903-015-0026-6.
  21. Pietropaoli D., Monaco A., D’Aiuto F., et al. Active gingival inflammation is linked to hypertension. Hypertens. 2020;38(10):2018–27. doi: 10.1097/HJH.0000000000002514.
  22. Munoz Aguilera E., Suvan J. Orlandi M., et al. Association Between Periodontitis and Blood Pressure Highlighted in Systemically Healthy Individuals: Results From a Nested Case-Control Study. Hypertens. 2021;77(5):1765–74. doi: 10.1161/HYPERTENSIONAHA.120.16790.
  23. Larvin H., Kang J., Aggarwal V.R., et al. The additive effect of periodontitis with hypertension on risk of systemic disease and mortality. J. Periodontol. 2022;93(7):1024–35. doi: 10.1002/JPER.21-0621.
  24. Konnecke H., Schnabel R.B., Walther C., et al. Eur J Med Res. 2022;27(1):181. doi: 10.1186/s40001-022-00811-y.
  25. Hwang S.Y., Oh H., Rhee M.Y., et al. Association of periodontitis, missing teeth, and oral hygiene behaviors with the incidence of hypertension in middle-aged and older adults in Korea: A 10-year follow-up study. J Periodontol. 2022;93(9):1283–93. doi: 10.1002/JPER.21-0706.
  26. Yildirim B.G., Aksit C., Mutlu M., et al. Severity and progression rate of periodontitis are associated with an increased risk of hypertension of patients attending a university clinic. BMC. Oral Health. 2022;22(1):627. doi: 10.1186/s12903-022-02637-w.
  27. Zhan Y., Jiao J., Jing W., et al.Association between periodontitis and hypertension: cross-sectional survey from the Fourth National Oral Health Survey of China (2015-2016). BMJ. Open. 2023;13(3):e068724. doi: 10.1136/bmjopen-2022-068724.
  28. Vazquez-Reza M., Lopez-Dequidt I., Ouro A., et al. Periodontitis is associated with subclinical cerebral and carotid atherosclerosis in hypertensive patients: A cross-sectional study. Clin Oral Investig. 2023 Apr 1. doi: 10.1007/s00784-023-04958-8.
  29. Sofi-Mahmudi A. Is periodontitis associated with hypertension? Evid Based Dent. 2020;21(4):132–3. doi: 10.1038/s41432-020-0137-z.
  30. Munoz Aguilera E., Suvan J., Buti J., et al. Periodontitis is associated with hypertension: a systematic review and meta-analysis. Cardiovasc Res. 2020;116(1):28–39. doi: 10.1093/cvr/cvz201.
  31. Xu K., Yu W., Li Y., et al. Association between tooth loss and hypertension: A systematic review and meta-analysis. J Dent. 2022;123:104178. doi: 10.1016/j.jdent.2022.104178.
  32. Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104. doi: 10.1093/eurheartj/ehy339.
  33. Клинические рекомендации Артериальная гипертензия у взрослых. РКО. 2020. [Clinical guidelines Arterial hypertension in adults. Russian Cardiology Society. 2020. (In Russ.)]. URL: https://scardio.ru/content/Guidelines/Clinic_rek_AG_2020.pdf
  34. Friedewald V.E., Kornman K.S., Beck J.D., et al. The American Journal of Cardiology and Journal of Periodontology editors’ consensus: periodontitis and atherosclerotic cardiovascular disease. J Periodontol. 2009;80:1021–32.
  35. Landi L., Grassi G., Sforza N.M., Ferri C. Italian working group on Hypertension and Periodontitis (Hy-Per Group). Hypertension and Periodontitis: An Upcoming Joint Report by the Italian Society of Hypertension (SIIA) and the Italian Society of Periodontology and Implantology (SIdP). High Blood Press. Cardiovasc Prev. 2021;28(1):1–3. doi: 10.1007/s40292-020-00430-w.
  36. Del Pinto R., Landi L., Grassi G., et al. Italian working group on Hypertension, Periodontitis (Hy-Per Group). Hypertension and Periodontitis: A Joint Report by the Italian Society of Hypertension (SIIA) and the Italian Society of Periodontology and Implantology (SIdP). High Blood Press. Cardiovasc Prev. 2021;28(5):427–38. doi: 10.1007/s40292-021-00466-6.
  37. Pietropaoli D., Cairo F., Citterio F., et al. Italian working group on Hypertension and Periodontitis (Hy-Per Group). Practical Guidelines for Patients with Hypertension and Periodontitis. High Blood Press. Cardiovasc Prev. 2023;30(1):7–16. doi: 10.1007/s40292-022-00553-2.
  38. Del Pinto R., Landi L., Grassi G., et al. Italian working group on Hypertension, Periodontitis (Hy-Per Group). Hypertension and periodontitis: A joint report by the Italian society of hypertension (SIIA) and the Italian society of periodontology and implantology (SIdP). Oral Dis. 2023;29(2):803–14. doi: 10.1111/odi.14009.
  39. Surma S., Romanczyk M., Witalinska-Labuzek J., et al. Periodontitis, Blood Pressure, and the Risk and Control of Arterial Hypertension: Epidemiological, Clinical, and Pathophysiological Aspects-Review of the Literature and Clinical Trials. Curr Hypertens Rep. 2021;23(5):27. doi: 10.1007/s11906-021-01140-x.
  40. Hwang S.Y., Oh H., Rhee M.Y., et al. Association of periodontitis, missing teeth, and oral hygiene behaviors with the incidence of hypertension in middle-aged and older adults in Korea: A 10-year follow-up study. J Periodontol. 2022;93(9):1283–93. doi: 10.1002/JPER.21-0706.
  41. Zhan Y., Jiao J., Jing W., et al. Association between periodontitis and hypertension: cross-sectional survey from the Fourth National Oral Health Survey of China (2015-2016). BMJ. Open. 2023;13(3):e068724. doi: 10.1136/bmjopen-2022-068724.
  42. Leng Y., Hu Q., Ling Q., et al Periodontal disease is associated with the risk of cardiovascular disease independent of sex: A meta-analysis. Front Cardiovasc Med. 2023;10:1114927. doi: 10.3389/fcvm.2023.1114927.
  43. Lanau N., Mareque-Bueno J., Zabalza M. Does Periodontal Treatment Help in Arterial Hypertension Control? A Systematic Review of Literature. Eur J Dent. 2021;15(1):168–73. doi: 10.1055/s-0040-1718244.
  44. Sharma S., Sridhar S., McIntosh A., et al. Periodontal therapy and treatment of hypertension-alternative to the pharmacological approach. A systematic review and meta-analysis. Pharmacol Res. 2021;166:105511. doi: 10.1016/j.phrs.2021.105511.
  45. Трухан Л.Ю., Трухан Д.И., Викторова И.А. Изменение органов и тканей полости рта при заболеваниях внутренних органов. Справочник поликлинического врача. 2011;7:8–14. [Trukhan L.Yu., Trukhan D.I., Viktorova I.A. Changes in the organs and tissues of the oral cavity in diseases of the internal organs. Spravochnik poliklinicheskogo vracha. 2011;7:8–14. (In Russ.)].
  46. Трухан Д.И., Викторова И.А., Трухан Л.Ю. Изменение органов и тканей полости рта при заболеваниях внутренних органов. М., 2012. 208 с. [Trukhan D.I., Viktorova I.A., Trukhan L.Yu. Changes in the organs and tissues of the oral cavity in diseases of the internal organs. M., 2012. 208 p. (In Russ.)].
  47. Трухан Д.И., Тарасова Л.В., Трухан Л.Ю. Изменения органов и тканей полости рта при заболеваниях сердечно-сосудистой системы и соединительной ткани, и их лекарственной терапии. Consilium Medicum. 2014;1:79–82. [Trukhan D.I., Tarasova L.V., Trukhan L.Yu. Changes in the organs and tissues of the oral cavity in diseases of the cardiovascular system and connective tissue, and their drug therapy. Consilium Medicum. 2014;1:79–82. (In Russ.)].
  48. Langari S.F., Hosseini S.R., Bijani A., et al. Association between antihypertensive drugs and the elderly’s oral health- related quality of life: Results of Amirkola cohort study. Caspian J Intern Med. 2022;13(3):582–88. doi: 10.22088/cjim.13.3.582.
  49. Ustaoglu G., Erdal E., Karas Z. Influence of different anti-hypertensive drugs on gingival overgrowth: A cross-sectional study in a Turkish population. Oral Dis. 2021;27(5):1313–19. doi: 10.1111/odi.13655.
  50. Ramon Y., Behar S., Kishon Y., Engelberg I.S. Gingival hyperplasia caused by nifedipine A preliminary report. Int J Cardiol. 1984;5:195–206. doi: 10.1016/0167-5273(84)90145-1.
  51. Damdoum M., Varma S.R., Nambiar M., Venugopal A. Calcium Channel Blockers Induced Gingival Overgrowth: A Comprehensive Review from a Dental Perspective. J Int Soc Prev Community Dent. 2022;12(3):309–22. doi: 10.4103/jispcd.JISPCD_57_22.
  52. Tamargo J., Segura J., Ruilope L.M. Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother. 2014;15(4):527–47. doi: 10.1517/14656566. 2014.879118.
  53. Burnier M., Bakris G., Williams B. Redefining diuretics use in hypertension: why select a thiazide-like diuretic? J Hypertens. 2019;37(8):1574–86. doi: 10.1097/HJH.0000000000002088.
  54. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32(12):2285–95. doi: 10.1097/HJH.0000000000000378.
  55. Chen P., Chaugai S., Zhao F., Wang D.W. Cardioprotective Effect of Thiazide-Like Diuretics: A Meta-Analysis. Am J Hypertens. 2015;28(12):1453–63. doi: 10.1093/ajh/hpv050.
  56. Pareek A.K., Messerli F.H., Chandurkar N.B., et al. Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring. J Am Coll Cardiol. 2016;67(4):379–89. doi: 10.1016/j.jacc.2015.10.083.
  57. Messerli F.H., Makani H., Benjo A., et al. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol. 2011;57(5):590–600. doi: 10.1016/j.jacc.2010.07.053.
  58. Трухан Д.И., Багишева Н.В. Рациональная фармакотерапия артериальной гипертензии в реальной клинической практике: диуретики сквозь призму лекарственной безопасности. Клинический разбор в общей медицине. 2023;4(4):48–59. [Trukhan D.I., Bagisheva N.V. Rational pharmacotherapy of arterial hypertension in real clinical practice: diuretics through the prism of drug safety. Klinicheskii razbor v obshchei meditsine. 2023;4(4):48–59. (In Russ.)]. doi: 10.47407/kr2023.4.4.00256.
  59. Roush G.C., Ernst M.E., Kostis J.B., et al. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65(5):1041–6. doi: 10.1161/HYPERTENSIONAHA.114.05021.
  60. Liang W., Ma H., Cao L., et al. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis. J Cell Mol Med. 2017;21(11):2634–42. doi: 10.1111/jcmm.13205.
  61. Lin J.-J., Chang H.-C., Ku C.-T., Chen H.-Y. Hydrochlorothiazide hypertension treatment induced metabolic effects in type 2 diabetes: a meta-analysis of parallel-design RCTs. Eur Rev Med Pharmacol Sci. 2016;20(13):2926–34.
  62. Lin Z., Li H.L., Tsoi M.F., Cheung B.M.Y. Hypokalaemia associated with hydro-chlorothiazide used in the treatment of hypertension in NHANES 1999-2018. J Hum Hypertens. 2022 May 6. doi: 10.1038/s41371-022-00704-x.
  63. Lin Z., Cheung B.M.Y., Tang V., Tsoi M.F. Incidence of severe hypokalaemia in patients taking indapamide. Intern Emerg Med. 2023;18(2):549–57. doi: 10.1007/s11739-023-03209-8.
  64. Musini V.M., Nazer M., Bassett K., Wright J.M. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014;5:CD003824. doi: 10.1002/14651858.CD003824.pub2.
  65. Мазуров А.Л., Трухан Д.И. Сравнительная характеристика индапамида и гидрохлоротиазида. Современные наукоемкие технологии. 2010;2:100–1. [Mazurov A.L., Trukhan D.I. Comparative characteristics of indapamide and hydrochlorothiazide. Sovremennye naukoemkie tekhnologii. 2010;2:100–1. (In Russ.)].
  66. Гидрохлоротиазид: новые данные о безопасности. [Hydrochlorothiazide: new safety data. (In Russ.)]. URL: http://www.rlsnet.ru/news_ 1791.htm
  67. Geanon J.D., Perkins T.W. Bilateral acute angle-closure glaucoma associated with drug sensitivity to hydrochlorothiazide. Arch Ophthalmol. 1995;113(10):1231–32. doi: 10.1001/archopht.1995.01100100019012.
  68. Roh Y.-R., Woo S.J., Park K.H. Acute-Onset Bilateral Myopia and Ciliochoroidal Effusion Induced by Hydrochlorothiazide. Korean J Ophthalmol. KJO. 2011;25(3):214–17. doi: 10.3341/kjo.2011.25.3.214.
  69. Трухан Д.И., Лебедев О.И. Изменение органа зрения при заболеваниях внутренних органов. М., 2014. 208 с. Trukhan D.I., Lebedev O.I. [Changes in the organ of vision in diseases of the internal organs. M., 2014. 208 p. (In Russ.)].
  70. Yang M.C. Lin K.Y. Drug-induced Acute Angle-closure Glaucoma: A Review. Drug-induced Acute Angle-closure Glaucoma: A Review. J Curr Glaucoma Pract. 2019;13(3):104–9. doi: 10.5005/jp-journals-10078-1261.
  71. Chen S.H., Karanjia R., Chevrier R.L., Marshall D.H. Bilateral acute angle closure glaucoma associated with hydrochlorothiazide-induced hyponatraemia. BMJ. Case Rep. 2014;2014:bcr2014206690. doi: 10.1136/bcr-2014-206690.
  72. Wu C., Pan H., Feng S., et al. Low-dose topiramate and hydrochlorothiazide-associated early acute myopia and angle narrowing: A case report. Front Med (Lausanne). 2023;10:1062160. doi: 10.3389/fmed.2023.1062160.
  73. Mahesh G., Giridhar A., Saikumar S.J., Fegde S. Drug-induced acute myopia following chlorthalidone treatment. Indian J Ophthalmol. 2007;55(5):386–88. doi: 10.4103/0301-4738.33830.
  74. Pottegard A., Hallas J., Olesen M., et.al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med. 2017;282(4):322–31. doi: 10.1111/joim.12629.
  75. Pedersen S.A., Gaist D., Schmidt S.A.J., et.al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol. 2018;78(4):673–81.e9. doi: 10.1016/j.jaad.2017.11.042.
  76. Garrido P.M., Borges-Costa J. Hydrochlorothiazide treatment and risk of non-melanoma skin cancer: Review of the literature. Rev Port Cardiol. (Engl Ed.). 2020;39(3):163–70. doi: 10.1016/j.repc.2019.07.008.
  77. Lecaros-Astorga D.A., Molina-Guarneros J.A., Rodriguez-Jimenez P., et.al. Hydrochlorothiazide use and risk of non-melanoma skin cancer in Spain: A case/non-case study. Int J Clin Pharmacol Ther. 2021;59(4):280–88. doi: 10.5414/CP203769.
  78. Becquart O., Guillot B., Bourrain J.-L., et al. Hydrochlorothiazide use and risk of skin cancers: A systematic review. Rev. Med. Interne. 2019;40(9):617–22. doi: 10.1016/j.revmed.2019.04.008.
  79. Letellier T., Le Borgne F., Kerleau C., et.al. Divat Consortium. Association between Use of Hydrochlorothiazide and Risk of Keratinocyte Cancers in Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2020;15(12):1804–13. doi: 10.2215/CJN.02560220.
  80. Carney K., Cousins M. Does hydrochlorothiazide increase the incidence of skin, lip and oral cancer in a UK population? Evid Based Dent. 2022;23(1):38–9. doi: 10.1038/s41432-022-0255-x.
  81. Eworuke E., Haug N., Bradley M., et al. Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States. JNCI. Cancer Spectr. 2021;5(2):pkab009. doi: 10.1093/jncics/pkab009.
  82. Rouette J., Yin H.., Pottegard A, et.al. Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer. Drug Saf. 2021;44(2):245–54. doi: 10.1007/s40264-020-01015-1.
  83. de Macedo Andrade A.C., Felix F.A., Franca G.M., et.al. Hydrochlorothiazide use is associated with the risk of cutaneous and lip squamous cell carcinoma: A systematic review and meta-analysis. Eur J Clin Pharmacol. 2022;78(6):919–30. doi: 10.1007/s00228-022-03299-x.
  84. Shao S.C., Lai C.C., Chen Y.H., et.al. Associations of thiazide use with skin cancers: a systematic review and meta-analysis. BMC. Med. 2022;20(1):228. doi: 10.1186/s12916-022-02419-9.
  85. Habel L.A., Achacoso N., Fireman B., et.al. Hydrochlorothiazide and risk of melanoma subtypes. Pharmacoepidemiol. Drug Saf. 2021;30(10):1396–401. doi: 10.1002/pds.5266.
  86. Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» (ФГБУ «НЦЭСМП» Минздрава России). Информационное письмо №4785 от 13 марта 2023 г. [Federal State Budgetary Institution «Scientific Center for Expertise of Medical Devices» (FGBU «NTsESMP» of the Ministry of Health of Russia). Information letter No. 4785 dated March 13, 2023. (In Russ.)]. URL: http://kcenter42.ru/doc/pismo/ls/2023/4785.pdf
  87. Levay I.D. Hydrochlorothiazide-induced pulmonary edema. Drug Intell Clin Pharm. 1984;18(3):238–39. doi: 10.1177/106002808401800311.
  88. Gonzalez G., Ligueros M., Castro P., et.al. Adult respiratory distress syndrome associated with hydrochlorothiazide: a report of 2 cases and review of the literature. Rev Med Chil. 1988;116(10):1047–53.
  89. Goetschalckx K., Ceuppens J., Van Mieghem W. Hydrochlorothiazide-associated noncardiogenic pulmonary oedema and shock: a case report and review of the literature. Acta Cardiol. 2007;62(2):215–20. doi: 10.2143/AC.62.2.2020246.
  90. Павлова Т.В. Роль диуретиков в лечении АГ. Справочник поликлинического врача. 2013;7–8:37–41. [Pavlova T.V. The role of diuretics in the treatment of hypertension. Spravochnik poliklinicheskogo vracha. 2013;7–8:37–41. (In Russ.)].
  91. Недогода С.В. Диуретики при артериальной гипертензии: ангелы и демоны. Российский кардиологический журнал. 2013;3:62–6. [Nedogoda S.V. Diuretics in arterial hypertension: angels and demons. Rossiiskii kardiologicheskii zhurnal. 2013;3:62–6. (In Russ.)].
  92. Трухан Д.И., Филимонов С.Н. Лечение артериальной гипертензии I-II стадий у пациентов с риском сердечно-сосудистых осложнений выше умеренного в реальной клинической практике: возможности индапамида в составе комбинированной терапии. Терапия. 2021;5(47):173–83. [Trukhan D.I., Filimonov S.N. Treatment of arterial hypertension of stages I-II in patients with a risk of cardiovascular complications above moderate in real clinical practice: the possibilities of indapamide as part of combination therapy. Therapy. 2021;5(47):173–83. (In Russ.)]. doi: 10.18565/therapy.2021.5.173-183.
  93. Zhang Y., Agnoletti D., Safar M.E., Blacher J. Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension. 2011;58(2):155–60. doi: 10.1161/HYPERTENSIONAHA.111.174383.
  94. Waeber B., Rotaru C., Feihl F. Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy. Expert Opin Pharmacother. 2012;13(10):1515–26. doi: 10.1517/14656566.2012.698611.
  95. Brodszky V., Nagy V., Farsang C., et.al. The efficacy of indapamide in different cardiovascular outcome--meta-analysis. Orv Hetil. 2007;148(26):1203–11. doi: 10.1556/OH.2007.28046.
  96. Nadhazi Z., Dezsi C.A. The Results of ACES (Antihypertensive Combinations’ Long Term Efficacy Comparing Study): Analysis of Metabolic Effects of Antihypertensive Combination Therapies. Clin Drug Investig. 2016;36(10):819–27. doi: 10.1007/s40261-016-0431-x.
  97. Трухан Д.И., Давыдов Е.Л., Дрокина О.В. Рациональная фармакотерапия артериальной гипертензии в реальной клинической практике сквозь призму лекарственной безопасности и мультиморбидности. Терапия. 2021;2(44):141–52. [Trukhan D.I., Davydov E.L., Drokina O.V. Rational pharmacotherapy of arterial hypertension in real clinical practice through the prism of drug safety and multimorbidity. Therapy. 2021;2(44):141–52. (In Russ.)]. doi: 10.18565/therapy.2021.2.141-152.
  98. Aubert I., Djian F., Rouffy J. Beneficial effects of indapamide on lipoproteins and apoproteins in ambulatory hypertensive patients. Am J Cardiol. 1990;65(17):77H–80. doi: 10.1016/0002-9149(90)90349-6.
  99. Akbari P., Khorasani-Zadeh A. 2023 Jan 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. URL: https://pubmed.ncbi.nlm.nih.gov/30422513
  100. Марцевич С.Ю., Кутишенко Н.П., Деев А.Д., Якусевич В.В. Изучение эффективности и переносимости препарата индап в сравнении с препаратами арифон и арифон ретард у больных мягкой и умеренной артериальной гипертонией, назначаемых как в виде монотерапии, так и в комбинации с ингибиторами АПФ. Многоцентровое, открытое, рандомизированное перекрестное исследование. Российский кардиологический журнал. 2006;2:73–7. [Martsevich S.Yu., Kutishenko N.P., Deev A.D., Yakusevich V.V. To study the efficacy and tolerability of indap in comparison with arifon and arifon retard in patients with mild and moderate arterial hypertension prescribed both as monotherapy and in combination with ACE inhibitors. Multicentre, open, randomized cross-over study. Rossiiskii kardiologicheskii zhurnal. 2006;2:73–7. (In Russ.)].
  101. Трухан Д.И., Павлова Т.В., Викторова И.А. Оптимизация немедикаментозного и медикаментозного воздействия на патогенетические факторы развития и течения артериальной гипертензии в рамках новой научно-исследовательской образовательной оздоровительной программы ПЕРСПЕКТИВА. Справочник поликлинического врача. 2012;11:18–22. [Trukhan D.I., Pavlova T.V., Viktorova I.A. Optimization of non-drug and drug effects on pathogenetic factors in the development and course of arterial hypertension in the framework of the new research educational health program PERSPECTIVE. Spravochnik poliklinicheskogo vracha. 2012;11:18–22. (In Russ.)].
  102. Сыров А.В., Минушкина Л.О. Выбор оптимального тиазидоподобного диуретика у пациентов с артериальной гипертензией. Терапия. 2021;1:172–80. [Syrov A.V., Minushkina L.O. Choice of optimal thiazide-like diuretic in patients with arterial hypertension. Therapy. 2021;1:172–80. (In Russ.)]. doi: 10.18565/therapy.2021.1.172-180.
  103. Остроумова О.Д., Полякова О.А., Листратов А.И. и др. Тиазидные и тиазидоподобные диуретики: как правильно сделать выбор? Кардиология. 2022;1:89–97. [Ostroumova O.D., Polyakova O.A., Listratov A.I. Thiazide and thiazide-like diuretics: how to make the right choice? Cardiologiya. 2022;1:89–97. (In Russ.)]. doi: 10.18087/cardio.2022.1.n1862.
  104. Полякова О.А., Остроумова О.Д., Араблинский А.В. Лекарственная безопасность и полиморбидность как важные составляющие рациональной фармакотерапии в кардиологии. Терапия. 2022;4(56):141–48. [Polyakova O.A., Ostroumova O.D., Arablinsky A.V. Drug safety and polymorbidity as important components of rational pharmacotherapy in cardiology. Therapy. 2022;4(56):141–48. (In Russ.)]. doi: 10.18565/therapy.2022.4.141-148.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. Algorithm of treatment of AH stages I-II [33]

Download (310KB)
Indexing metadata

Copyright (c) 2023 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies